Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Levamisole as an immunomodulator drug has been demonstrated to improve the immune response to Hepatitis B virus (HBV) vaccination in hemodialysis patients. The aim of this study was to evaluate the effect of levamisole supplementation on tetanus-diphtheria (Td) vaccine response rate in hemodialysis patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shiraz University of Medical Sciences
• Treatments: Levamisole; Vaccines

Criteria

Inclusion Criteria:

• being under regular hemodialysis for more than 3 months

• unprotective baseline levels of antitetanus IgG

Exclusion Criteria:

• tetanus diphtheria (Td) vaccination in past year

• leukopenia (WBC<1500 cells/mcL)

• immunosuppressive drug exposure in past 2 months

• recent hospitalization or history of transfusion of blood products in the past 3 months.